Lynparza, a PARP inhibitor, is expected to be approved as a treatment for prostate and pancreatic cancer in Korea.

According to related industries, AstraZeneca is currently expanding the license to Lynparza (Olaparib) for two indications of maintenance therapy for patients with metastatic castration-resistant prostate cancer with a homologous recombination recovery (HRR) mutation and patients with metastatic pancreatic cancer with a BRCA mutation (gBRCAm). Approval is expected in July.

Lynparza's indication for prostate cancer was approved by the U.S. FDA in May of last year and in December of 2019 for pancreatic cancer.

The efficacy of this drug in prostate cancer has been